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ABSTRACT Antibody (Ab) affinity maturation enables an individual to maintain immunity to an increasing number of patho-
gens within the limits of a total Ig production threshold. A better understanding of this process is critical for designing vaccines
that generate optimal Ab responses to pathogens. Our study describes a simple flow-cytometric method that enumerates virus-
specific germinal center (GC) B cells as well as their AC50, a measure of Ab avidity, defined as the antigen concentration required
to detect 50% of specific B cells. Using a model of mouse Ab responses to the influenza A virus hemagglutinin (IAVHA), we ob-
tained data indicating that AC50 decreases with time postinfection in an affinity maturation-dependent process. As proof of prin-
ciple of the utility of the method, our data clearly show that relative to intranasal IAV infection, intramuscular immunization
against inactivated IAV in adjuvant results in a diminished GCHA B cell response, with increased AC50 correlating with an in-
creased serum Ab off-rate. Enabling simultaneous interrogation of both GCHA B cell quantity and quality, this technique
should facilitate study of affinity maturation and rational vaccine design.
IMPORTANCE Though it was first described 50 years ago, little is known about how antibody affinity maturation contributes to
immunity. This question is particularly relevant to developing more effective vaccines for influenza A virus (IAV) and other vi-
ruses that are difficult vaccine targets. Limitations in methods for characterizing antigen-specific B cells have impeded progress
in characterizing the quality of immune responses to vaccine and natural immunogens. In this work, we describe a simple flow
cytometry-based approach that measures both the number and affinity of IAV-binding germinal center B cells specific for the
IAVHA, the major target of IAV-neutralizing antibodies. Using this method, we showed that the route and form of immuniza-
tion significantly impacts the quality and quantity of B cell antibody responses. This method provides a relatively simple yet
powerful tool for better understanding the contribution of affinity maturation to viral immunity.
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Antibodies (Abs) are a critical component of the immune re-sponse to viruses. Abs accelerate viral clearance in primary
infections and often provide life-long immunity to subsequent
infections with antigenically similar viruses. As with every bi-
ological function, the capacity of the immune system to syn-
thesize Abs is finite. Total serum Ig concentrations in mammals
are typically maintained near 12 mg/ml, with only minor in-
creases associated with aging (1). Since serum Abs may be in-
duced by thousands of pathogens during a long life span, the
efficacy of Abs specific for each pathogen is at a premium.
Efficiency is optimized by the process of Ab affinity maturation
(2). A thousandfold increase in Ab affinity implies (this has
never been carefully tested) that 1,000-fold less antibody would
exert an equal biological effect.
During Ab affinity maturation, activated naive B cells form
structures called germinal centers (GC), where, with appropriate
T cell help, they randomly diversify their Ab-encoding genes.
Higher-affinity clones win the competition for survival and spawn
long-lived plasma cells andmemory B cells, which when activated
can experience further affinity maturation (3, 4).
Historically, characterization of B cell responses has been
largely limited tomeasuring Ab responses in serum and secretions
and sequencing antigen-specific Ig genes from B cell hybridomas.
Recent advances enable discrimination of B cells according to an-
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tigen binding and activation status (5–7). New techniques rapidly
characterize individual Ab genes from single B cells to interrogate
B cell populations (8–10). These advances are creating a revolu-
tion in the understanding of B cell immunity.
Here, we studied B cell responses to influenza A virus (IAV), a
leading cause of death in the United States, with associated yearly
costs of roughly $50 billion. It is particularly important to under-
stand Ab responses to IAV. Rapid evolution of the hemagglutinin
(HA), the target of the most potent virus-neutralizing Abs (11,
12), necessitates frequent updates to vaccine formulation and lim-
its vaccine efficacy, particularly in the elderly (13, 14).
Pioneering DNA sequencing of Ab genes fromHA-specific hy-
bridomas by Gerhard, Caton, Weigert and colleagues provided
the initial information on the diversity of Ab gene usage in B cell
responses to pathogens (15). Later research built on this founda-
tion by establishing the validity of using fluorescentHA to identify
specific B cells by flow cytometry (16) and using HA-based B cell
sorting to determine HA-specific Ab sequences from single cells
and populations (16–19).
Building on these advances, we developed a flow cytometry-
based method that enables the characterization of surface Ig ex-
pressing GC-resident B cells following primary IAV infection and
immunization. We demonstrate and validate that by titrating a
recombinant IAV protein hemagglutinin (HA) probe while stain-
ing B cells, we can also derive a measure of the population’s anti-
body avidity for HA, defined as the antigen concentration re-
quired to detect 50% of HA-specific B cells (AC50). We can show
that AC50 decreases over time and its change is due to affinity
maturation. As proof of principle of the power of this simple yet
robust approach, we demonstrate that pulmonary infection in-
duces a quantitatively and qualitatively superior Ab response
compared to the standard route of vaccination by intramuscular
(i.m.) injection. This approach enables simultaneous measure-
ment of the GC B cell response magnitude and avidity over time
and represents a powerful tool for better understanding of affinity
maturation and vaccine design.
RESULTS
Recombinant HA can specifically identify HA-specific GC
B-cells. To identify HA-specific B cells, we used recombinant HA
from A/Puerto Rico/8/34 (PR8) secreted by insect cells with its
carboxy-terminal domainmodified to promote trimerization and
enable detection with an anti-His tag monoclonal antibody
(MAb). This HA preparation (rHAPR8) is remarkably native, as
shown by biochemical analysis in conjunction with a panel of
MAbs to assess conformation (20). To establish the properties of
rHAPR8 as a B cell probe, we screened hybridoma cell lines to
identify a line that expresses cell surface Ig, which is unusual (21).
H17-L7, an HA Cb site-specific hybridoma, exhibits surface IgG
expression (Fig. 1A) and binds rHAPR8 in a dose-dependent fash-
ion but does not bind to the serologically distantH5 rHAVietnam 04,
demonstrating the specificity of staining with rHAPR8 (Fig. 1B
and C).
We next stained mediastinal lymph node (MLN)-resident B
cells from B6 mice infected intranasally (i.n.) with PR8. We fo-
cused on GC B cells (defined as B220 CD38lo GL7hi), as they
exhibit a distinct differentiation marker profile and retain strong
surface Ig expression (22). Among MLN CD3-negative cells
(90% B220), rHAPR8 staining was essentially limited to GC B
cells (Fig. 1D). To confirm the specificity of rHAPR8 binding toGC
B cells, we infected mice with a reassortant IAV (J1) with 7 PR8
genes but a serologically distinct HA from an H3 virus (A/Hong
Kong/1/68). Little reactivity was observed from J1-infected GC B
cells up to an rHAPR8 concentration of 66 nM, providing an upper
concentration limit for detectingAb-specific binding of this probe
to GC B cells (Fig. 1E).
HA-specific GC B cells exhibit different responses in local
versus central lymphoid organs. Using a staining concentration
of 66 nMrHAPR8we quantified theHA-specificGCB cell response
following i.n. infection in theMLNs and spleen. HA-specific GCB
cells were first detected at 7 days postinfection (dpi) in MLNs and
10 dpi in the spleen. Numbers of splenic HA-reactive GC B cells
peaked at 14 dpi, while theirMLN-resident counterparts peaked a
week later (Fig. 2A). Expressed as a fraction of total GC B cells,
splenic B cells peaked at 21 dpiwhileMLNB cells continued to rise
in frequency at 28 dpi (Fig. 2B).
These findings confirm the utility of rHAPR8 in tracking HA-
specific responses and clearly demonstrate distinct kinetics of the
HA-specificGCB cell response in proximal versus distal lymphoid
organs.
AC50 of HA-specific GC B cells can be used as a proxy for
population avidity for PR8HA.As initially described for hapten-
specific B cells (23), the binding of rHAPR8 to GC B cells should
obey the law of mass action and thereby provide a measure of
Ab affinity for HA. In theory, for any B cell, Ab affinity should
equal the rHAPR8 concentration that gives half-maximal binding
(rHAPR850). There is no need to reach saturation to define AC50, as
B cell receptor (BCR)-specific and “nonspecific” antigen binding
is a continuum, where “nonspecific” means low-affinity binding
of germline BCRs. However, during an immune response, Abs
with high affinity will outcompete those with lower affinity.
Therefore, our maximum binding is the binding at a concentra-
tionwhere naive BCRs do not bind.While each B cell can be tested
only for binding to a single rHAPR8 concentration, at the popula-
tion level, if cell surface Ig levels are equally distributed among B
cell clones, the average Ab affinity will track the rHAPR8 concen-
tration that detects half the number of HA-specific B cells. We
define this as the 50% antigen concentration (AC50) (Fig. 3A). It is
important to emphasize that since HA-specific GC B cells com-
prise a heterogeneous population of clones with various affinities
and surface Ig expression, AC50 provides (at best) the mean affin-
ity of Abs expressed by the HA-specific B cell population studied.
We verified the validity of AC50 measurements by comparing
the calculated H17-L7 AC50 versus purified H17-L7 MAb affinity
determined via ELISA (Fig. 3B). We observed remarkable agree-
ment between AC50 (1.1 nM) and KD (equilibrium dissocation
constant) (0.6 nM), supporting the validity of our approach. We
next compared the avidities of 10 MAbs generated 5 days after
primary infection (24) to the AC50 of GC B cells 7 days after i.n.
infection. Again, there was strong concordance of AC50 with the
average avidity, with both values being ~10 nM (Fig. 3D).
We next investigated the extent towhich the AC50 is influenced
by the fraction of HA-specific cells in a B cell population, an im-
portant factor given the low and variable fraction of HA-specific B
cell in ex vivo populations used for studying HA-specific GC B cell
responses. We mixed naive splenocytes with H17-L7 hybridoma
in different proportions and determined the binding curves and
respective AC50s. The AC50s were statistically indistinguishable
between the different mixtures (Fig. 3E).
Based on these findings, we conclude that by simple antigen
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titration in flow-cytometric staining, we can derive a value, the
AC50, that provides a measure of the affinity of the B cell Ig
receptor.
AC50 characterization of HA-specific GC B cells. We next
used AC50 to characterize maturation of specific GC B cell re-
sponses in MLNs and spleens during IAV infection. GC B cells at
28 dpi had a significantly higher frequency of HA reactivity at
lower rHAPR8 concentrations than 14-dpi counterparts (Fig. 4A),
with a clear increase in HA-specific GC B cell frequency and a
decrease of AC50 over 4 weeks following infection (Fig. 4B). AC50
decreased approximately 30-fold, from 10 nM at 7 dpi to 0.36 nM
at 28 dpi (Fig. 4C).
While we were unable to obtain reliable AC50 data for
spleen-resident B cells at early and late time points due to low
frequencies of HA-specific GC B cells (Fig. 2B), we did calculate
AC50 at 14 and 21 dpi, which follow a surprisingly similar pat-
tern of AC50 decrease to MLN-resident GC B cells (Fig. 4D).
Importantly, we cannot trivially attribute the time-dependent
decrease of AC50 in MLN and splenic GC B cells to temporal
increases in GC B cell surface Ig levels, which are statistically
indistinguishable between 14 and 28 dpi (Fig. 4E) (note that
likely due to steric hindrance, we were unable to costain GC B
cells with rHAPR8 and anti-Ig Abs to directly correlate Ig sur-
face levels with antigen binding).
A potential pitfall of HA staining is the requirement to treat
cells with neuraminidase to prevent HA binding to the abundant
cell surface terminal sialic acids. To circumvent this problem, we
used an rHA with a substitution in the sialic acid binding site that
prevents sialic acid binding (rHAPR8-Y98F) (19). This enabledGCB
cell staining without neuraminidase treatment of cells and gave
FIG 1 Recombinant HA can specifically identify HA-specific GC B cells. Briefly, we treated cells with receptor-destroying enzyme for 60 min at 37°C to remove
sialic acid from the cell surface to minimize nonspecific binding. We stained cells first with surface MAb, then with rHA, and finally with anti-6His MAb to
detect rHA binding. (A) Representative flow plots demonstrate that H17 L7, a PR8 HA-specific hybridoma, retains high levels of surface Ig expression. (B)
Representative flow plots indicate that H17 L7 binds strongly to A/Puerto Rico/8/1934 molecular clone rHA (rHAPR8) but not to A/Vietnam/1203/2004 rHA
(rHAViet 04), a serologically distinct HA. (C) Plot of percent 6His-positive cells versus rHAPR8 concentration illustrating that H17 L7 reacts to rHAPR8 in a
dose-dependent fashion. At 14 days after PR8 i.n. infection, MLNs were excised and dispersed into single-cell suspensions, and GC B cells were stained using the
rHA approach. (D) representative plots depict gating strategy to observe GC B cells based on B220 GL-7 CD38 surface expression. Only GC B cells reacted
specifically to rHAPR8. (E) B6mice were i.n. infected with anH3N1 reassortant (J1), andMLN-resident GCB cells were stained with rHAPR8. Representative flow
plots of MLN resident GC B cell 6His staining show that J1-responding GC B cells did not react to rHAPR8 at staining concentrations up to 66 nM, providing
the maximum staining concentration of rHAPR8 that can be used to identify H1 HA-specific B cells with confidence. Data represent 3 independent experiments.
Flow Based-Afﬁnity Determination
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essentially identical results (see Fig. S1 in the supplemental mate-
rial).
Using the rHAPR8-Y98F probe, it was further possible to costain
with anti-Ig Abs, allowing us to correlate IgG surface levels and
rHA binding.We show that the amount of IgG on the surface of B
cells does not determine rHA binding (see Fig. S2 in the supple-
mental material), strengthening our conclusion that AC50 is not
trivially due to different levels of surface B cell receptor.
Lastly, we used themean fluorescent intensity (MFI) of stained
cells to calculate the AC50. As predicted from the law of mass
action, this yielded results similar to those obtained by using the
percent positive cells (an example is shown in Fig. S3 in the sup-
plementalmaterial) but exhibited greater variability between sam-
ples. Therefore, in all additional experiments, we calculated the
AC50 based on the percent positive cells.
AC50 increase is drivenby affinitymaturation. If the observed
decrease in AC50 is due to affinity maturation, it should not occur
in mice with activation-induced deaminase knockout (AID/
mice), which are incapable of somatic hypermutation (25). In
response to intrperitoneal (i.p.) injection of UV light-inactivated
PR8, WTmice generated a robust HA-specific GC B cell response
exhibiting 12-fold-decreased AC50 (5.8 nM to 0.49 nM) between
14 and 28 dpi (Fig. 5A and B). As seen in other studies, the AID/
mice generate a large germinal-center reaction, with a robust HA-
specific GC B cell response (26). However, the AID/ response’s
AC50 remained constant from 14 to 28 dpi (Fig. 5). Since Ig class
switching is also abrogated in AID/ mice, these data strongly
support the conclusion that kinetic changes in AC50 reflect the
selection of higher-affinity HA-specific clones by classical B cell
somatic mutation and selection mechanisms.
Intramuscular vaccination with inactivated PR8 and adju-
vant produces an inferior HA-specific GC B cell response. As
proof of principle of the utility of AC50 for characterizing immune
responses, we compared i.n. infection with infectious PR8 to a
single intramuscular (i.m.) injection of UV-inactivated PR8 in
Titermax adjuvant. The latter is known to be less protective
against lethal PR8 challenge (27). Following i.m. immunization,
serum anti-HA Abs were always detected, confirming successful
vaccination (data not shown). HA-specific GC B cell responses
were uniformly observed in the most proximal popliteal draining
lymph nodes, 33% of the time in the more distant inguinal nodes,
but never within the spleen (Fig. 6A), indicating only localized
generation of HA-reactive GC B cells.
The HA-specific B cell response in the inguinal LN was similar
in frequency to that in i.n. infection (Fig. 6B) but was numerically
inferior; i.m. vaccination of mice induced only 5% and 7% of GC
B cells compared to i.n. infection at 14 and 28 dpi, respectively
(Fig. 6C). While the popliteal LN B cell numbers induced by i.m.
immunization were too low to establish AC50 due to lymph node
size, the inguinal LNGCB cell response decreases in AC50 from 14
to 28 after i.m. vaccination with similar kinetics to infected re-
sponses (~7 to 10-fold decrease, vaccination to infection, respec-
tively). However, at both time points, the GC B cell AC50 after
vaccination was approximately 4-fold higher than those respond-
ing to i.n. infection (Fig. 6D). Thus, i.m. vaccination resulted in a
14- to 20-fold lower HA-specific GC B cell response that was also
4-fold higher in AC50 than that achieved with i.n. infection.
These findings predict that i.m. immunization will generate
less anti-HA Ab of lower affinity. We tested this prediction by
surface plasmon resonance (SPR) analysis of serumAb responses,
which provides a measure of total Ab responses and accurately
measures the average Ab off-rates, typically the most important
factor in Ab affinity. In agreement with ourmeasurement of GC B
cell numbers, serum antibody HA-binding activity from i.m.-
vaccinated mice was 38% and 17% lower than in sera from in-
fected animals at 14 dpi and 28 dpi, respectively (Fig. 6E). Further
confirming our AC50 data, Ab off-rates decreased in vaccinated
mice between days 14 and 28, suggesting increased affinity, but
retained statistically significant faster off-rates compared to
postinfection sera (Fig. 6F). The disparity in off-rates (1.3-fold
and 1.4-fold higher at days 14 and 28 postvaccination, respec-
tively) remained stable relative to values for postinfection sera,
similar to observed GC B cell AC50 (Fig. 6D).
Taken together, these data support the validity of the AC50
method for determining Ab avidity and demonstrate its utility for
analyzing immunity to viral infection and immunization.
FIG 2 HA-specific GC B cells exhibit different responses in local versus
central lymphoid organs. At the indicated times after PR8 i.n. infection, we
removed MLN or spleens, dispersed them into single-cell suspensions, and
stainedGCB cells with rHA. Line graphs indicate the absolute number (A) and
frequency (B) of GC B cells specifically binding rHAPR8 (based on a staining
concentration of 66 nM) over time in the MLNs and spleens. MLN GC B cells
binding rHAPR8 form earlier (7 dpi) but peak later (21 dpi) than spleen-
resident GC B cells, which do not appear until after 7 dpi and peak at 14 dpi.
Data are representative of 3 to 6 independent experiments.
Frank et al.
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DISCUSSION
While a large body of research carried out over decades supports
the importance of HA-specific antibody in the control of IAV
infection (28), little is known about the immunological mecha-
nisms that drive HA-specific B cell responses. In this study, we
demonstrate how flow-cytometric characterization of HA-
specific GC B cell responses provides a wealth of information on
the kinetics, magnitude, and most importantly the quality of the
HA B cell immune response to IAV infection.
Our approach hinges on the quality and specificity of the anti-
gen probe used to identify B cells. We were fortunate to have
collaborative access to recombinant HA preparations that are ho-
mogeneously extremely well folded (19, 20), minimizing the non-
specific binding of denatured probe to GCB cells. As Bardelli et al.
originally reported (18), we found it necessary to treat GC B cells
with neuraminidase to reduce nonspecific binding of rHA to tol-
erable levels. Neuraminidase treatment did not have a significant
effect on the staining of the cell surface antigens analyzed in this
study (data not shown). Using a novel rHAPR8 probe with a single
amino acid mutation (Y98F) in the sialic acid binding site that
abolishes sialic acid binding (19), we could confirm that neur-
aminidase treatment does not affect the accuracy of the method
(see Fig. S1 in the supplemental material). Still, it is advantageous
to avoid neuraminidase treatment in terms of time, expense, and
reproducibility, and such receptorless HA probes are clearly pre-
ferred for all future studies (with the one caveat that they may
display less binding to broadly neutralizing Abs with CDRs [com-
plementarity determining regions] that extend into the sialic acid
binding site [29]). Obviously, for other antigenic proteins, our
approach is limited by the need to have a pure, well-folded, and
homogeneous probe and also the requirement to prevent its bind-
ing to B cell non-Ig receptors, either by modifying the receptor
properties of the probe or by removing/blocking the receptor on
the B cell surface.
Our upper limit of rHAPR8-specific binding was 66 nM, raising
the question of howmany biologically relevant lower-affinityHA-
specific B cells we are missing. Since Ab binding to antigen is a
continuum, there is no absolute limit between specific and non-
specific binding. Practically, however, if naive B cells generate Abs
at reasonably high affinity prior to affinitymaturation, this will set
FIG3 AC50 ofHA-specificGCB cells can be used as a proxy for population avidity to PR8HA. (A)Overview of AC50. GCB cell rHA staining frequency is plotted
against rHAPR8 concentration. Nonspecific binding by J1-responding GCB cells occurs at concentrations above 66 nM rHAPR8. Using this dose as themaximum
specific staining of HA-specific GCB cells, we estimated the half-maximal specific binding rHAPR8 concentration. This provides amolar rHAPR8 value we call the
AC50, a proxy measurement of population avidity for rHAPR8. (B) Representative titration curve of H17 L7 HA-specific hybridoma using rHAPR8 (red plots) or
by ELISA of purified H17 L7 antibody to plated whole virus (blue plots). (C) Bar graph depicting the calculated AC50 compared to ELISA affinity. Values are
within 1.8-fold of each other. (D) Comparison of HA-specific GC B cell AC50, 7 days after PR8 i.n. infection, with mean affinity of 9 different 5-dpi MAbs. The
AC50 andmean affinity are statistically indistinguishable. (E) AC50 for H17 L7HA-specific hybridomamixed in different proportions with naive splenocytes and
assayed using rHAPR8. AC50 is independent of the proportion of specific cells. Data are representative of 2 or 3 independent experiments.
Flow Based-Afﬁnity Determination
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a biologically relevant affinity threshold for relevant affinities,
since they will outcompete Abs with lower affinities during the
immune response. For PR8 HA, we found that B6 mice possess
enough naive B cells expressing Abs with KD of 1  108 M to
generate a strong response by simply expanding these cells by 5 to
7 dpi (Fig. 3D). This is consistent with studies that examined 6-dpi
primary affinities of mouse MAbs specific for HA (24) or the
equivalent receptor protein from vesicular stomatitis virus (24,
30). Further, naive humans seem to generate Abs to IAV HA with
a similar affinity range (10). To place this affinity into functional
context, half of HA epitopes will be boundwhen serum reaches an
Ab concentration of 10 nM (108 M, or 6 1012 molecules/ml).
Fifty years ago, Fazekas de St. Groth reported that by day 14 fol-
lowing immunization, rabbits already possessed up to 1015 Abs/ml
(31). Thus, even without affinity maturation, primary Ab re-
sponses to HA should exert considerable biological activity.
Therefore, while it is certain that we are missing a substantial
number of low-avidity B cells, it is likely that the Ab with KD at or
below 10 nM that we detect are the most biologically relevant
species responding to IAV.
Given that the overall Ab response to IAV appears to be highly
biased toward HA (15), it is surprising that HA-specific cells seem
to comprise a small fraction of GC B cells (15% or less). There are
several possible explanations, each of which likely contributes to
this observation. First, although GCs are induced by virus, this
does not guarantee that every activated B cell in the GC was acti-
vated by IAV antigens. It is possible that IAV infection induces a
self-specific response, and we cautiously remind readers that a
Nobel Prize was awarded to Jerne for his theory that Ab responses
induce a strong anti-idiotypic response (32, 33), though there
could be many other self antigens of greater importance.
Second, we are unaware of definitive data on the relative abun-
dance of antibodies specific for various IAV gene products (or
other viruses). Though M1 and the polymerases are not highly
immunogenic, NP and NS1 are clearly major immunogens fol-
lowing live virus infection (34). Further, many hybridomas iso-
lated from IAV-immunized mice by Gerhard and colleagues were
specific for poorly defined glycolipid components of the host cells
used to grow the virus (35).
Third, our rHAPR8 preparation clearly is not identical to HA in
the immunizing virus. The rHAPR8 is folded with remarkable fi-
delity, but as an insect cell product, it lacks the complex carbohy-
FIG 4 AC50 characterization of HA-specific GC B cells. At indicated times after PR8 i.n. infection, we excised MLN or spleens, dispersed them into single-cell
suspensions, and stained GC B cells with rHA. (A) Representative flow plots depict MLN resident GC B cell reactivity to graded concentrations of rHAPR8. GC
B cells at 28 dpi react more strongly to lower staining concentrations than those at 14 dpi. (B) Titration curves of MLN-resident GC B cells to rHAPR8 following
i.n. PR8 infection. Data represent the frequency of positive cells plotted against rHAPR8 concentration. (C) AC50 was calculated for each titration curve and is
presented as the concentration (nanomolar) of rHAPR8 required to reach 50%maximal binding at the indicated time points. MLN-resident GC B cells decrease
AC50 to rHAPR8 29-fold between 7 and 28 days postinfection, or a 140% increase each day. (D) AC50 of spleen-resident GC B cells at 14 and 21 dpi following i.n.
infection.Despite different frequencies and kinetics of response,HAAC50 is similar to that ofMLNGCB cells. (E)At 14 and 28 dpi,MLNswere excised, dispersed
into single-cell suspensions, and stained with anti-IgG FcMAb. The graph illustrates normalizedMFI levels of IgG Fc expression of GCB cells relative to naive
B cells that express no IgG (set as baseline MFI) at 14 and 28 dpi. No significant difference in per-cell-surface IgG expression occurs between 14 and 28 days
postinfection. All data are representative of 3 to 7 replicate experiments.
Frank et al.
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drates present on HA produced by vertebrate cells (36). However,
it should be noted that rHAPR8-Y98F, expressed from amammalian
cell line, should have complex carbohydrates and detects a similar
frequency of reactive B cells. As soluble proteins, both probes
would be unable to detect MAbs that require the geometric array
of HA present on virions or infected cell material.
Fourth, GC B cell makeup may not accurately predict GC-
derived plasma cell frequency, and our current staining approach
does not interrogate the GC-independent extrafollicular plasma
cell response, which has been observed in B6 mice following IAV
infection (37). Further study will be required to better correlate
the HA-reactive GC B cell response to HA-reactive serum Abs.
We observed distinct kinetics of HA-specific GC B cells when
comparing theMLN and the spleen.While HA-specific GCB cells
were detected earlier in the MLN (7 dpi), the splenic HA-specific
GC response peaked earlier and was larger in magnitude (Fig. 2A)
but contained a smaller fraction of HA-specific cells (Fig. 2B).
Boyden et al. (38) reported prominent differences in local versus
central GC responses to pulmonary IAV infection. Differential
kinetics of antigen delivery (39) likely contributes to this phenom-
enon, but there are probably also local factors, including the na-
ture and magnitude of help provided by follicular T helper cells.
The MLN GC HA-specific response AC50 increases approxi-
mately 30-fold between 7 and 28 dpi (Fig. 4C), a process that is
almost certainly driven by affinity maturation, as indicated by the
stable AC50 in AID/mice over time (Fig. 5C). Outside the pio-
neering efforts of Fazekas de St. Groth (31), there are surprisingly
limited data on the degree of affinity maturation of antiviral re-
sponses or its biological effects. It is notoriously difficult to deter-
mine the average affinity of Ab responses in biological fluids,
where the amount of the specific Ab is difficult to determine. In-
deed, this was one of the driving factors for our developing the
AC50 approach. Admirably eager to challenge dogma, Roost and
colleagues reported the absence of Ab affinity maturation in
mouse responses to vesicular stomatitis virus (VSV) (30), and
Zinkernagel questioned its relevance to antiviral immune re-
sponses (40).
Our AC50 of 1 nM for 21-dpi responses in mice is in good
agreement with values from Fazekas de St. Groth et al. (41), who
observed average Ab dissociation constants of 0.75 nM for 21-dpi
responses to PR8 in rabbits (note that this is after conversion from
the CGS units typically used by Fazekas de St. Groth in his publi-
cations). Recent studies using SPR analysis demonstrate that Ab
off-rates decline in humans following IAV immunization (42),
FIG5 AC50 decrease is driven by affinitymaturation.We injected B6 andAID/mice i.p. withUV-inactivated PR8, and 14 and 28 days later, we excised spleens
and dispersed them into single-cell suspensions. We then stained GC B cells with rHA. (A and B) Titration of B6 GC B cells and AID/GC B cells, respectively,
using rHAPR8 at 14 and 28 dpi, plotting the frequency of positive cells versus rHAPR8 concentration. (C) AC50 was calculated for each titration curve and is
presented as the concentration (nanomolar) of rHAPR8 required to reach 50%maximal binding at indicated time points. WhileWTGC B cells decrease AC50 to
rHAPR8 by 12-fold between 14 and 28 days postinfection, AID/ GC B cell AC50 remains stable. Data are representative of 3 independent experiments.
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extending previous work using resistance to denaturants to
roughly measure Ab avidity (43). An enormous volume of new
data from MAbs obtained from human B cells conclusively links
increased affinity with somatic hypermutation (44–46). Thus, the
doubts about the relevance of Ab affinity maturation in antiviral
immunity expressed by Zinkernagel (40) are not supported by
more recent studies.
AC50 determination enables rapid comparisons of the kinetics
and affinity quality ofHA responses to a variety of source antigens,
e.g., inactivated viral immunogens used for vaccination. There is
considerable room for improvement in IAV vaccination, which at
best provides only partial protection even in years with good an-
tigenic matching of vaccine with circulating virus (47).
To validate AC50 in vaccine evaluation, we compared i.n. in-
fection with PR8 to a single i.m. vaccination, which provides less
effective protection against lethal challenge (27). Intramuscular
vaccination generates only local GC B cell responses, with incon-
sistent distal DLN involvement and no splenic resident response
(Fig. 6A), pointing to poor trafficking of immunogens (Fig. 6C).
Further, GC B cells responding to i.m. versus i.n. vaccination gen-
erate B cells with 4-fold less avid AC50 at 14 and 28 days postvac-
cination, despite undergoing a 10-fold affinity increase in the in-
tervening period (Fig. 6D). Together, this suggests while the
affinity maturation process remains effective after i.m. vaccina-
tion, deficiencies in the early stages of GC formation leads to a
smaller and lower-quality starting pool of HA-specific GC B cells.
Notably, i.p. immunization with inactivated virus generates a GC
B cell response similar to i.n. infection (data not shown), demon-
strating that neither infectious virus nor robust viral replication is
essential to generate strong responses. A goal of future studies is to
better understand the contribution route, dose, and form of im-
munization to generate optimal B cell responses.
The inferior GC B cell response quantity and quality are sup-
ported by serum total binding as determined by SPR analysis
FIG 6 Intramuscular vaccination with inactivated PR8 and adjuvant produces an inferior HA-specific GC B cell response. We injected mice bilaterally with a
total dose of 2.5 107 TCID50/mouse (pre-UV inactivation) diluted 1:1 with Titermax gold adjuvant or infected mice i.n. with 50 TCID50 per mouse. At 14 and
28 dpi, we removed lymphoid organs draining the site of injection, the inguinal LN, and/or popliteal LN (i.m. vaccination) ormediastinal LN (i.n. infection), and
spleens, dispersed them into single-cell suspensions, and stained GC B cells with rHA. (A) Representative flow plots depict total GC B cell response (top) as well
as HA binding (bottom). Red dot plots indicate no HA control staining, while blue dot plots represent HA staining at 66 nM rHAPR8. The table depicts the
frequency with which an HA-specific GC B cell response was seen in the lymphoid organ following i.m. vaccination. (B and C) Bar graphs depicting numbers of
HA-specificGCB cells and frequency ofHA-specificGCB cells per tissue.Mice vaccinated i.m. have sporadic distal LN involvement and no splenicHA response,
while productively infected mice have large HA-specific populations in the draining MLN as well as the distal spleen. (D) AC50 for each condition. GC B cells
responding to i.m. vaccination have ~4-fold-higher AC50 than those formed to productive i.n. infection. Scatter plots of HA binding signal (E) and Ab off-rate
(F). Serum from 14 and 28 days after i.m. PR8-vaccinated and i.n. PR8-infected mice were tested by surface plasmon resonance (SPR) analysis to determine Ab
signal and off-rates. Serum from i.m.-vaccinated mice had an amount of HA binding antibody and had significantly higher off-rates at both 14 and 28 dpi. Data
are representative of 2 to 4 independent experiments.
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(maximum resonance units [RU]) and dissociation off-rates
(Fig. 6F), where serum Ab concentration and quality following
vaccination are also lower than after infection. Based on the small
HA GC B cell response (5% and 7% of the infected response at 14
and 28 dpi, respectively), we were surprised to note a much
smaller disparity in serumAb concentration (38% and 17% lower
at 14 and 28 dpi, respectively). This samedisparity in quality is also
noted between AC50 and serum off-rates, but to a much lower
extent (average 4-fold-higher AC50 compare to 1.4-fold-lower se-
rum Ab off-rate). These observations clearly highlight the com-
plexities in using cellular response information to predict serum
Ab characteristics, where unclear relationships of GC to plasma
cells, per-cell antibody production variability, and the contribu-
tion of GC-independent Ab responses collectively muddy the wa-
ters. Further, the contribution of Ab on-rates to affinity matura-
tion is also unknown.
Further refining of this technique to interrogate the antibody-
secreting B cell compartment will enable us to better explore the
relationship between the GC B cell response and the serum anti-
body compartment. To date, we have been unable to specifically
stain permeabilized cells with rHA probes, but we have not ex-
hausted all possible combinations of fixing and permeabilizing
reagents, particularly given the high rate at which the latter are
being introduced. Further, it might be possible to capture secreted
antibodies by a chimeric reagent that binds Igwith one arm and an
abundant B cell surface molecule with another arm, as has been
developed for cytokine analysis (48).
When different vaccine formulations/regimens are being com-
pared, one aim is always to obtain high titers of Abs with high
affinity. However, it is not trivial to dissect polyclonal Ab avidities
with the technologies available today. SPR analysis is a useful
method that can provide off-rates of serum Abs of unknown con-
centrations. The AC50 method presented here should facilitate
analysis of Ab avidity in many research laboratories and during
initial optimizations of vaccine preparations.
In summary, we describe a simple method to simultaneously
quantitate HA-reactive GC B cells while providing a reasonably
accurate measure of their Ab affinity. This approach can poten-
tially facilitate the rational design and improvement of vaccines
for viruses and other important immunogens.
MATERIALS AND METHODS
rHAPR8. Recombinant PR8 Mount Sinai hemagglutinin (rHAPR8) was
expressed and purified as previously described (19, 36). The PR8 HA
protein possessed a C-terminal thrombin cleavage site, a “foldon” se-
quence, and a His tag at the extreme C terminus for protein purification
and detection. In later experiments, we also used a PR8 HA with a Y98F
mutation that abrogates binding activitywith a biotinC-terminal tag (19).
For Biacore serum affinity measurements, we used recombinant PR8
H1N1 HA obtained through BEI Resources (NIAID).
Antibody reagents. Allophycocyanin (APC)-conjugated and purified
mouse anti-6His (clone AD 1.1.10) was purchased from Abcam. Fluo-
rescein isothiocyanate (FITC)-conjugated rat anti-mouse CD38 (90/
CD38), APC- and phycoerythrin (PE)-conjugated rat anti-mouse GL7
(GL7), PE-Cy7- and Pacific blue-conjugated rat anti-mouse CD45R/B220
(RA3-6B2), and Pacific blue-conjugated hamster anti-mouse CD3
(500A2) were purchased from BD Biosciences. APC-conjugated strepta-
vidin was purchased from eBioscience. DyLight 6470-conjugated Affini-
Pure goat anti-mouse IgG (all subclasses), Fc fragment specific, was pur-
chased from Jackson ImmunoResearch.
Mice. C57BL/6 mice were purchased from Taconic Farms or Charles
River Laboratories. For all experiments, 6- to 12-week-old AID/mice
(25) were kindly provided by A. Nussenzweig with gracious permission of
T. Honjo. All mice were housed under specific-pathogen (including mu-
rine norovirus [MNV], mouse parvovirus [MPV], and mouse hepatitis
virus [MHV])-free conditions. All animal procedures were approved by
and performed in accordancewith theNIAID andCBERAnimalCare and
Use Committee guidelines.
Viruses and infections. For intranasal infections, mice were anesthe-
tized in isoflurane and inoculated intranasally with 50TCID50 (50% tissue
culture infective doses) of influenza virus A H1N1 PR8 (Mt. Sinai strain)
or influenza virus A J1, a PR8H3 reassortant (49). For i.p. injections, virus
was UV irradiated for 4 min, and 4  108 TCID50 (pre-UV inactivation
titer) was administered by intraperitoneal injection. For intramuscular
challenge, UV-inactivated virus was mixed at a ratio of 50:50 with Titer-
max gold adjuvant (Sigma), and 5  106 TCID50 (pre UV-inactivation
titer) were injected bilaterally into the caudal thigh.
Flow-cytometric analysis. At various times after injection/infection,
the mediastinal lymph nodes, inguinal lymph nodes, and/or spleens were
harvested from euthanized mice. Tissues were dispersed into single-cell
suspensions and treated with red blood cell lysis buffer (Sigma) prior to
staining with antibodies. In order to account for the number of specific B
cells, a low input cell number (on average 10,000 to 20,000 antigen-
specific B cells per tube) combinedwith excess rHA probe and large wash-
ing volumes was used. When stained with recombinant HA (rHA), cells
were treated with either filtrate-derived (1:20 dilution) or purified
(6 mU/ml in RPMI) neuraminidase from Vibrio cholerae for 60 min at
37°C in RPMI (Gibco) to remove surface sialic acid from cells. Cells were
stained with primary surface antibodies (30 min, 4°C), with a complete
nine-step titration of rHAPR8 for each experiment (starting at 66 nM
down to 0.0066 nM) (60 min 4°C), and finally with anti-6 antibodies
(30 min 4°C), to detect rHAPR8 binding. Each experiment included ap-
propriate fluorescent minus one (FMO), unstained, and single-stained
controls to ensure proper staining and gates that provided the internal
controls for the titration. Stained cells were analyzed on an LSR-II flow
cytometer (BDBiosciences). For staining with rHAPR8-Y98F (19), the same
procedure was followed but with neuraminidase treatment omitted and
with final staining performed using streptavidin-APC conjugated
(30 min, 4°C).
AC50 determination. Using a titration of rHAPR8 probe with J1
(H3N1)-reactive germinal center B cells, the maximal specific binding of
the HAPR8 probe was established. rHAPR8 probe was titrated over a dose
range of 66 nM to 0.66 nM, and data were plotted as the frequency of
rHAPR8 probe-positive GC B cells. Using a single one-site binding with
Hill slope calculation, the 50% maximal binding rHAPR8 probe concen-
tration was established to evaluate the antigen concentration that stains
50% of the maximum specific population, or AC50. Where noted, the
geometric mean fluorescent intensity (MFI) was used instead of percent-
age of the population. In these experiments, AC50 is defined as the antigen
concentration staining at 50% of the maximal MFI.
ELISA. Ninety-six-well plates (Immunlon 4HBX) were used to test
MAb reactivity. Plates were coated overnight at 4°C with saturating
amounts of purified PR8 HA in phosphate-buffered saline (PBS), then
washed three times with PBS containing 0.05% (vol/vol) Tween 20, and
blocked with PBS–0.5% fetal bovine serum (FBS) for 2 h at room tem-
perature. MAb was titrated from nondetectable to saturating binding and
incubated with virus for 2 h at room temperature. Rat anti-mouse kappa
conjugated to horseradish peroxidase (Southern Biotech) was used to
detectMAb binding. Plates were developed for 5min using TMB (tetram-
ethylbenzidine) substrate (KPL biomedical) and halted by the addition of
0.1 N HCl, after which plates were read at 450 nm. Ab avidities were
determined using Prism software, and all avidities reported demonstrated
excellent fit for one-site binding with Hill slope curve fitting (R2 0.98).
SPR analysis of serum antibody. Steady-state equilibrium binding of
polyclonal sera was monitored at 25°C using a ProteOn surface plasmon
resonance biosensor (Bio-Rad Labs). The recombinant functional PR8
H1N1-HA0 (BEI resources) was coupled to a GLC sensor chip using
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amine coupling with 100 resonance units (RU) in the test flow cells. Sam-
ples of 60 l of freshly prepared polyclonal sera at various concentrations
were injected at a flow rate of 30 l/min (120-s contact time). Flow was
directed over a mock surface to which no protein was bound, followed by
the recombinant functional PR8 H1N1-HA0 coupled surface. Responses
from the protein surface were corrected for the response from the mock
surface and for responses froma separate, buffer-only injection.MAb2D7
(anti-CCR5) was used as a negative-control antibody in various binding
experiments. Binding kinetics for the sera and the data analysis was ana-
lyzed using Bio-Rad ProteON manager software (version 2.1.1). Affinity
measurements were calculated using the heterogeneous model.
Statistics. Ab avidities were determined using Prism software, and all
avidities reported demonstrated excellent fit for one-site bindingwithHill
slope curve fitting (R2 0.98). Significances were calculated byGraphPad
Prism (GraphPad Software, Inc.) using unpaired Student’s t test.
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